INCY:NAS (USA) Also trade in: Austria Germany UK

Incyte Corp

$ 73.96 -0.36 (-0.48%)
Volume: 1,689,855 Avg Vol (1m): 1,206,618
Market Cap $: 15.85 Bil Enterprise Value $: 14.44 Bil
P/E (TTM): 145.02 P/B: 8.19
Earnings Power Value 7.54
Net Current Asset Value 5.22
Tangible Book 7.29
Projected FCF 10.69
Median P/S Value 169.51
Graham Number 9.15
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 9/10

Current vs industry vs history
Cash-to-Debt 39.81
Equity-to-Asset 0.73
Debt-to-Equity 0.02
Debt-to-EBITDA 0.21
Interest Coverage 100.73
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.71
DISTRESS
GREY
SAFE
Beneish M-Score -2.72
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 29.49%
WACC 10.48%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 8.26
Net Margin % 5.82
ROE % 6.28
ROA % 4.50
ROC (Joel Greenblatt) % 40.27
3-Year Total Revenue Growth Rate 35.70
3-Year Total EBITDA Growth Rate 20.60
3-Year EPS w/o NRI Growth Rate 157.10

» INCY's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:INCY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare OCSE:GEN OCSE:NZYM B NAS:NKTR XBRU:UCB NAS:BMRN NAS:BIVV HKSE:02269 NAS:JUNO NAS:ALNY NAS:BGNE NAS:JAZZ XMCE:GRF.P NAS:BLUE HKSE:01177 NAS:SGEN NAS:AVXS NAS:NBIX NAS:ALKS NAS:SAGE NAS:EXEL
Traded in other countries ICY.Germany 0J9P.UK
Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Ratios

Current vs industry vs history
PE Ratio (TTM) 145.02
Forward PE Ratio 38.91
N/A
PE Ratio without NRI 145.02
Price-to-Owner-Earnings 267.00
PB Ratio 8.19
PS Ratio 8.44
Price-to-Free-Cash-Flow 60.77
Price-to-Operating-Cash-Flow 47.44
EV-to-EBIT 123.58
EV-to-EBITDA 84.05
EV-to-Revenue 7.68
Current Ratio 4.31
Quick Ratio 4.29
Days Inventory 23.23
Days Sales Outstanding 59.66
Days Payable 402.73

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.50

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.14
Price-to-Projected-FCF 6.92
Price-to-Median-PS-Value 0.44
Price-to-Graham-Number 8.08
Earnings Yield (Joel Greenblatt) % 0.81

More Statistics

Revenue (TTM) (Mil) $ 1,881.88
EPS (TTM) $ 0.51
Beta 1.32
Volatility % 43.37
52-Week Range $ 57 - 88.83
Shares Outstanding (Mil) 214.26

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N